BeOne Medicines AG (NASDAQ:ONC) is one of the High Growth International Stocks to Buy Now. On February 9, Rebecca Liang from Bernstein reiterated a Buy rating on the stock with a $414 price target. Earlier, on February 4, Barclays also reiterated a Buy rating on BeOne Medicines AG (NASDAQ:ONC) and raised the price target from $385 to $394.
The bullish sentiment follows the first-in-world approval of BeOne’s Sonrotoclax in China to treat adults with two hard-to-treat blood cancers. These include relapsed/refractory mantle cell lymphoma (MCL) and relapsed/refractory chronic lymphocytic leukemia (CLL). The approval in China was based on the MCL study and CLL/SLL study presented at the 2025 ASH conference.
The MCL study demonstrated 52.4% overall response rate per independent review, and the CLL/SLL study showed 77% ORR per independent review. Management noted that the approval in China is part of a global rollout strategy.
Rebecca Liang from Bernstein believes BeOne Medicines AG (NASDAQ:ONC) to be undervalued considering its pipeline. She noted that “the pipeline is not recognized by the market,” and highlighted Sonrotoclax as “potential best-in-class status.”
BeOne Medicines AG (NASDAQ:ONC), based in Switzerland, is a global oncology company focused on discovering and developing innovative cancer treatments for hematology and solid tumors worldwide.
While we acknowledge the potential of ONC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
